PIMJS
NBIX icon

PKO Investment Management Joint-Stock’s Neurocrine Biosciences NBIX Stock Holding History

PKO Investment Management Joint-Stock’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Hold
1,400
– – 0.02% 221
2026
Q1 		$184K Buy
1,400
+100
+8% +$13.3K 0.02% 213
2025
Q4 		$184K Buy
+1,300
New +$188K 0.01% 215

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

PKO Investment Management Joint-Stock's NBIX Position: Q2 2026 in Review

PKO Investment Management Joint-Stock held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 1,400 shares worth $236K. The position accounts for 0.02% of the portfolio, ranked #221.

PKO Investment Management Joint-Stock first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • PKO Investment Management Joint-Stock held 1,400 shares of Neurocrine Biosciences worth $236K as of Q2 2026.
  • PKO Investment Management Joint-Stock left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of PKO Investment Management Joint-Stock's portfolio in Q2 2026, its #221 holding.
  • PKO Investment Management Joint-Stock first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on PKO Investment Management Joint-Stock's 13F filing for Q2 2026, filed 20 Jul 2026.